NF-κB Rel subunit exchange on a physiological timescale.
Matthew BiancalanaEviatar NatanMichael J LenardoAlan R FershtPublished in: Protein science : a publication of the Protein Society (2022)
The Rel proteins of the NF-κB complex comprise one of the most investigated transcription factor families, forming a variety of hetero- or homodimers. Nevertheless, very little is known about the fundamental kinetics of NF-κB complex assembly, or the inter-conversion potential of dimerised Rel subunits. Here, we examined an unexplored aspect of NF-κB dynamics, focusing on the dissociation and reassociation of the canonical p50 and p65 Rel subunits and their ability to form new hetero- or homodimers. We employed a soluble expression system to enable the facile production of NF-κB Rel subunits, and verified these proteins display canonical NF-κB nucleic acid binding properties. Using a combination of biophysical techniques, we demonstrated that, at physiological temperatures, homodimeric Rel complexes routinely exchange subunits with a half-life of less than 10 min. In contrast, we found a dramatic preference for the formation of the p50/p65 heterodimer, which demonstrated a kinetic stability of at least an order of magnitude greater than either homodimer. These results suggest that specific DNA targets of either the p50 or p65 homodimers can only be targeted when these subunits are expressed exclusively, or with the intervention of additional post-translational modifications. Together, this work implies a new model of how cells can modulate NF-κB activity by fine-tuning the relative proportions of the p50 and p65 proteins, as well as their time of expression. This work thus provides a new quantitative interpretation of Rel dimer distribution in the cell, particularly for those who are developing mathematical models of NF-κB activity.
Keyphrases
- signaling pathway
- lps induced
- pi k akt
- nuclear factor
- oxidative stress
- induced apoptosis
- transcription factor
- inflammatory response
- nucleic acid
- randomized controlled trial
- poor prognosis
- computed tomography
- binding protein
- magnetic resonance imaging
- mesenchymal stem cells
- drug delivery
- immune response
- cell death
- cell free
- metal organic framework